ATE376839T1 - Verfahren zur regulierten hyperstimulation der eierstöcke und pharmazeutisches kit zur verwendung in diesem verfahren - Google Patents

Verfahren zur regulierten hyperstimulation der eierstöcke und pharmazeutisches kit zur verwendung in diesem verfahren

Info

Publication number: ATE376839T1
Authority: AT; Austria
Prior art keywords: substance; progestogen; precursor; administration; parenteral
Prior art date: 2001-12-21

Application number

AT02792102T

Other languages

English (en)

Inventor

Bennink Herman Coelingh

Evert Bunschoten

Original Assignee

Pantarhei Bioscience Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-21

Filing date

2002-12-20

Publication date

2007-11-15

2002-12-20 Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv

2007-11-15 Application granted granted Critical

2007-11-15 Publication of ATE376839T1 publication Critical patent/ATE376839T1/de

Links

210000001672 ovary Anatomy 0.000 title 1
230000001105 regulatory effect Effects 0.000 title 1
239000000126 substance Substances 0.000 abstract 6
239000002243 precursor Substances 0.000 abstract 3
239000000583 progesterone congener Substances 0.000 abstract 3
206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 abstract 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
230000021121 meiosis Effects 0.000 abstract 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 abstract 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 abstract 1
230000008485 antagonism Effects 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
229940028334 follicle stimulating hormone Drugs 0.000 abstract 1
230000008217 follicular development Effects 0.000 abstract 1
230000003054 hormonal effect Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
230000002028 premature Effects 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Endocrinology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT02792102T 2001-12-21 2002-12-20 Verfahren zur regulierten hyperstimulation der eierstöcke und pharmazeutisches kit zur verwendung in diesem verfahren ATE376839T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01205068		2001-12-21

Publications (1)

Publication Number	Publication Date
ATE376839T1 true ATE376839T1 (de)	2007-11-15

Family

ID=8181501

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02792102T ATE376839T1 (de)	2001-12-21	2002-12-20	Verfahren zur regulierten hyperstimulation der eierstöcke und pharmazeutisches kit zur verwendung in diesem verfahren

Country Status (7)

Country	Link
US (1)	US20060217315A1 (de)
EP (2)	EP1455831B1 (de)
AT (1)	ATE376839T1 (de)
AU (1)	AU2002358346A1 (de)
CA (1)	CA2471388A1 (de)
DE (1)	DE60223284T2 (de)
WO (1)	WO2003055524A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MEP39308A (en)	2002-06-07	2011-02-10	Ares Trading S A Chateau De Vaumarcus	Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
GB0214793D0 (en) *	2002-06-26	2002-08-07	Disperse Technologies Plc	Biliquid foam entrapment
WO2012120535A2 (en) *	2011-02-03	2012-09-13	Sanzyme Limited	A composition comprising highly purified chorionic gonadotropin, it's formulation and uses of the same
EP2717880B1 (de) *	2011-06-13	2016-12-14	Parthenogen SAGL	Selektive zns-freisetzung von mifepriston (ru486) zur modulierung des zeitpunktes des spontanen lh-ansteigs während follikularer stimulationszyklen
US20150272622A1 (en)	2011-12-22	2015-10-01	Previvo Genetics, Llc	Recovery and processing of human embryos formed in vivo
US9216037B2 (en)	2013-06-21	2015-12-22	Previvo Genetics, Llc	Uterine lavage for embryo retrieval
AU2014230467A1 (en) *	2013-03-14	2015-10-22	Laboratoire Hra-Pharma	Method for scheduling ovulation
RU2603319C1 (ru) *	2015-09-09	2016-11-27	Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ лечения больных с тяжелыми формами синдрома гиперстимуляции яичников
WO2021133430A1 (en) *	2019-12-23	2021-07-01	Augusta University Research Institute, Inc.	Progesterone formulation to trigger ovulation and provide luteal phase support

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2651435A1 (fr) *	1989-09-07	1991-03-08	Roussel Uclaf	Nouvelle utilisation de composes anti-progestomimetiques.

2002
- 2002-12-20 AT AT02792102T patent/ATE376839T1/de not_active IP Right Cessation
- 2002-12-20 DE DE60223284T patent/DE60223284T2/de not_active Expired - Fee Related
- 2002-12-20 EP EP02792102A patent/EP1455831B1/de not_active Expired - Lifetime
- 2002-12-20 AU AU2002358346A patent/AU2002358346A1/en not_active Abandoned
- 2002-12-20 WO PCT/NL2002/000853 patent/WO2003055524A1/en not_active Ceased
- 2002-12-20 EP EP07116815A patent/EP1862182A2/de not_active Withdrawn
- 2002-12-20 US US10/499,505 patent/US20060217315A1/en not_active Abandoned
- 2002-12-20 CA CA002471388A patent/CA2471388A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2471388A1 (en)	2003-07-10
AU2002358346A1 (en)	2003-07-15
US20060217315A1 (en)	2006-09-28
EP1862182A2 (de)	2007-12-05
DE60223284D1 (de)	2007-12-13
EP1455831B1 (de)	2007-10-31
WO2003055524A1 (en)	2003-07-10
DE60223284T2 (de)	2008-07-31
EP1455831A1 (de)	2004-09-15

Similar Documents

Publication	Publication Date	Title
TAKETANI et al.	1983	Epidermal growth factor stimulates cell proliferation and inhibits functional differentiation of mouse mammary epithelial cells in culture
Saperas et al.	1990	Central action of recombinant interleukin-1 to inhibit acid secretion in rats
González-Manchón et al.	1991	Activin-A modulates gonadotropin-releasing hormone secretion from a gonadotropin-releasing hormone-secreting neuronal cell line
MY118652A (en)	2004-12-31	Use of diazepines for preparing medicines for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors
Simoni et al.	1995	FSH in therapy: physiological basis, new preparations and clinical use
DE60223284D1 (de)	2007-12-13	Verfahren zur regulierten hyperstimulation der eierstöcke und pharmazeutisches kit zur verwendung in diesem verfahren
IL162614A0 (en)	2005-11-20	Liposomal delivery of vitamin e based compounds
Gessl et al.	1994	Growth hormone-prolactin-thyrotropin-secreting pituitary adenoma in atypical McCune-Albright syndrome with functionally normal Gs alpha protein
Kovacs et al.	2010	Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization
Kanamori et al.	1987	Gonadotropin receptors in the postovulatory ovary of amago salmon (Oncorhynchus rhodurus)
Hanna et al.	2015	Phosphodiesterase 3 (PDE3) inhibition with cilostazol does not block in vivo oocyte maturation in rhesus macaques (Macaca mulatta)
ATE491464T1 (de)	2011-01-15	Lh zur verwendung der erhaltung einer oder mehreren schwangerschaften durch induktion der bildung des sekundären gelbkörpers.
US20110281802A1 (en)	2011-11-17	Composition for treatment and prevention of hair loss and premature graying of hair
BR9906975A (pt)	2000-10-17	Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
Miller et al.	1987	L-triiodothyronine stimulates growth by means of an autocrine factor in a cultured growth-hormone-producing cell line.
Schnatz	1985	Neuroendocrinology and the Ovulation Cycle
SOWERS et al.	1976	Prolactin response to N3im-methyl-thyrotropin releasing hormone in euthyroid subjects
Hutz et al.	1991	Estradiol‐induced follicular atresia in rhesus monkeys is not prevented by exogenous gonadotropins
ATE153859T1 (de)	1997-06-15	Somatotropin zur erhoehung der reproduktiven leistung in rinder
Kessel et al.	1987	The ovarian granulosa cell as a follicle-stimulating hormone target tissue
Binet et al.	1980	Calcitonin-responsive adenylate cyclase in cultured F9 embryonal carcinoma cells
Koizumi	1996	The role of the hypothalamus in neuroendocrinology
Magnusson et al.	1983	Oxygen consumption by rat oocytes and cumulus cells during induced atresia
RU2002133285A (ru)	2004-09-10	Средство для регуляции репродуктивной функции и половой активности позвоночных животных и способ регуляции репродуктивной функции и половой активности позвоночных животных
LIANG et al.	1994	Modulatory role of epidermal growth factor in follicle-stimulating hormone-induced DNA synthesis in cultured rat granulosa cells

Legal Events

Date

Code

Title

Description

2008-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1455831

Country of ref document: EP

2010-09-15

REN

Ceased due to non-payment of the annual fee